InflaRx Q3 2026: Net Loss Narrows to €2.4M, Cash Runway Extended to End of 2029
IFRX has more than doubled off its 52-week low of $0.798.
Summary
InflaRx reported a Q3 2026 net loss of €2.4 million (vs €12.3 million a year ago) and €153.3 million in total available funds, which management says funds operations through the end of 2029.
Key Events · Earnings and Guidance · IFRX
-
Q3 Loss Narrows Sharply
Net loss for the three months ended September 30, 2026 was €2.4 million versus €12.3 million a year earlier; the nine-month loss was €18.7 million versus €35.0 million.
-
Runway Extended to End of 2029
€81.3 million in cash plus €71.9 million in marketable securities gives €153.3 million of available funds, which management says funds planned operations through the end of 2029.
-
Going Concern Language Included
The MD&A states a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern, despite the stated multi-year runway.
-
Warrant Liability Is Non-Cash
Liabilities to warrant holders rose to €10.7 million from €5.8 million at December 31, 2025 through fair value remeasurement of the February 2025 pre-funded warrants — no new warrants issued and no cash movement.
Analysis · IFRX · Life Sciences
The May 2026 raise did its job: with €81.3 million in cash plus €71.9 million in marketable securities (€153.3 million total available funds), management now says it can fund operations through the end of 2029 — a multi-year runway for a company whose lead asset izicopan does not start Phase 2 in AAV until early 2027. The quarter itself was clean, with a net loss of €2.4 million versus €12.3 million a year ago, helped by winding down GOHIBIC sales and a €2.6 million non-cash gain on remeasuring the February 2025 pre-funded warrants. The offsetting item is the boilerplate going-concern paragraph in the MD&A, which sits awkwardly next to a four-year runway and reflects the company's historical losses rather than an imminent funding gap. As for the €10.7 million warrant liability, it is a mark-to-market entry, not new dilution or cash owed.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IFRX was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.1M. The 52-week trading range was $0.80 to $2.95. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.